nach oben

Pituitary

Erschienen in:

01.12.2007 | Case Report

Management of type 2 diabetes mellitus associated with pituitary gigantism

verfasst von: Omar Ali, Swati Banerjee, Daniel F. Kelly, Phillip D. K. Lee

Erschienen in: Pituitary | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Pituitary gigantism, a condition of endogenous growth hormone (GH) hypersecretion prior to epiphyseal closure, is a rare condition. In the adult condition of GH excess, acromegaly, the occurrence of type 2 diabetes mellitus (T2DM) and diabetic ketoacidosis (DKA) have been reported, with resolution following normalization of GH levels. We report the case of a 16-year-old male with pituitary gigantism due to a large invasive suprasellar adenoma who presented with T2DM and DKA. Despite surgical de-bulking, radiotherapy and medical treatment with cabergoline and pegvisomant, GH and insulin-like growth factor-I (IGF-I) levels remained elevated. However, the T2DM and recurrent DKA were successfully managed with metformin and low-dose glargine insulin, respectively. We review the pathophysiology of T2DM and DKA in growth hormone excess and available treatment options.

Bergson BA, Eden S, Ernest I, Oden A et al (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223:327–335

Alexander L, Appleton D, Hall R et al (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 12:71–79

Etxabe J, Gaztambide S, Latorre P, Vazquez JA (1993) Acromegaly: an epidemiological study. J Endocrinol Invest 16:181–187PubMed

Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2:29–41PubMedCrossRef

Sönksen PH, Greenwood FC, Ellis JP et al (1967) Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab 27:1418–1430PubMedCrossRef

Møller N, Jørgensen JO, Abildgaard N, Ørskov L, Schmitz O, Christiansen JS (1991) Effects of growth hormone on glucose metabolism. Horm Res 36(suppl 1):32–35PubMed

Arya KR, Pathare AV, Chadda M, Menon PS (1997) Diabetes in acromegaly—a study of 34 cases. J Indian Med Assoc 95:546–547PubMed

Ezzat S, Forster MJ, Berchtold P et al (1994) Acromegaly. Clinical and biochemical features in 500 patients. Medicine 73:233–240PubMedCrossRef

Szeto CC, Li KY, Ko GT et al (1997) Acromegaly in a woman presenting with diabetic ketoacidosis and insulin resistance. Int J Clin Pract 51:476–477PubMed

10.

Katz JR, Edwards R, Khan M, Conway GS (1996) Acromegaly presenting with diabetic ketoacidosis. Postgrad Med J 72:682–683PubMed

11.

Westphal SA (2000) Concurrent diagnosis of acromegaly and diabetic ketoacidosis. Endocr Pract 6:450–452PubMed

12.

Kuzuya T, Matsuda A, Sakamoto Y et al (1983) A case of pituitary gigantism who had two episodes of diabetic ketoacidosis followed by complete recovery of diabetes. Endocrinol Jpn 30:329–334PubMed

13.

Alvi NS, Kirk JM (1999) Pituitary gigantism causing diabetic ketoacidosis. J Pediatr Endocrinol Metab 12:907–909PubMed

14.

Holt RI, Simpson HL, Sonksen PH (2003) The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med 20:3–15PubMedCrossRef

15.

Møller N, Gjedsted J, Gormsen L et al (2003) Effects of growth hormone on lipid metabolism in humans. Growth Horm IGF Res 13(Suppl A):S18–S21PubMedCrossRef

16.

Kaiser N, Leibowitz G, Nesher R (2003) Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. Pediatr Endocrinol Metab 16:5–22

17.

McGarry JD, Dobbins RL (1999) Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42:128–138PubMedCrossRef

18.

Newton CA, Raskin P (2004) Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med 164:1925–1931PubMedCrossRef

19.

Arafah BM, Nasrallah MP (2001) Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 8:287–305PubMedCrossRef

20.

Zada G, Kelly DF, Cohan P et al (2003) Endonasal transsphenoidal approach for pituitary adenomas and other sellar lesions: an assessment of efficacy, safety, and patient impressions. J Neurosurg 98:350–358PubMed

21.

Ahmed S, Elsheikh M, Stratton IM et al (1999) Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol 50:561–567CrossRef

22.

Thorner MO (2003) Controversy: radiotherapy for acromegaly. Clin Endocrinol 58:136–137CrossRef

23.

Wass JA (2003) Radiotherapy in acromegaly: a protagonists viewpoint. Clin Endocrinol 58:128–131CrossRef

24.

Barkan AL (2003) Radiotherapy in acromegaly: the argument against. Clin Endocrinol 58:132–135CrossRef

25.

Racine M, Barkan A (2003) Somatostatin analogs in medical treatment of acromegaly. Endocrine 20:271–278PubMedCrossRef

26.

Koop BL, Harris AG, Ezzat S (1994) Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 130:581–586PubMedCrossRef

27.

Webb SM, Ortega E, Rodriguez-Espinosa J et al (2001) Decreased insulin requirements after LAR-octreotide but not after lanreotide in an acromegalic patient. Pituitary 4:275–278PubMedCrossRef

28.

Trainer PJ, Drake WM, Katznelson L et al (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171–1177PubMedCrossRef

29.

Drake WM, Parkinson C, Besser GM, Trainer PJ (2001) Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends Endocrinol Metab 12:408–413PubMedCrossRef

30.

Friend KE (2002) Acromegaly: a new therapy. Cancer Control 9:232–235PubMed

31.

Schreiber I, Buchfelder M, Droste M et al (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75–82PubMedCrossRef

32.

Zhou G, Myers R, Li Y et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–1174PubMedCrossRef

33.

Hawley SA, Gadalla AE, Olsen GS, Hardie DG (2002) The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51:2420–2425PubMedCrossRef

34.

Hardie DG, Carling D (1997) The AMP-activated protein kinase: fuel gauge of the mammalian cell? Eur J Biochem 246:259–273PubMedCrossRef

35.

Lochhead PA, Salt IP, Walker KS et al (2000). 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49:896–903PubMedCrossRef

36.

Hundal RS, Krssak M, Dufour S et al (2000) Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 49:2063–2069PubMedCrossRef

37.

Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100:328–341PubMedCrossRef

38.

Perriello G, Misericordia P, Volpi E et al (1994) Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43:920–928PubMedCrossRef

39.

Lupi R, Del Guerra S, Fierabracci V et al (2002) Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes. 51(Suppl 1):S134–S137PubMedCrossRef

40.

Wiernsperger NF, Bailey CJ (1999) The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 58 Suppl 1:31–39; discussion 75–82

41.

Ikeda T, Iwata K, Murakami H (2000) Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol 59:887–890PubMedCrossRef

42.

Drake WM, Rowles SV, Roberts ME et al (2003) Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 149:521–527PubMedCrossRef

43.

Kay JP, Alemzadeh R, Langley G et al (2001) Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50:1457–1461PubMedCrossRef

44.

Lee A, Morley JE (1998) Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 6:47–53PubMed

Titel: Management of type 2 diabetes mellitus associated with pituitary gigantism
verfasst von: Omar Ali
Swati Banerjee
Daniel F. Kelly
Phillip D. K. Lee
Publikationsdatum: 01.12.2007
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 4/2007
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-007-0060-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2007

Diagnosis and treatment of pediatric Cushing’s disease

Pituitary development and physiology

Guest Editorial: Special Issue on Pediatric Pituitary

Isolated growth hormone deficiency

Genetics of septo-optic dysplasia